REVIEW
Management of lipid disorders in diabetes: an overview of current recommendations
1
Department of Internal Medicine, Diabetology, and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poland
Submission date: 2025-07-09
Acceptance date: 2026-03-13
Online publication date: 2026-04-08
Corresponding author
Przemysław Marcin Witek
Department of Internal Medicine, Diabetology, and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poland, Poland
Department of Internal Medicine, Diabetology, and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poland, Poland
KEYWORDS
TOPICS
ABSTRACT
Lipid disorders are highly prevalent among patients with diabetes. Despite their prevalence and well-established role in progression of cardiovascular (CV) diseases, dyslipidemia still remains poorly controlled. Dyslipidemia in diabetes is characterized by a distinct lipid profile: in type 2 diabetes, moderately elevated triglycerides and triglyceride-rich lipoproteins, normal or slightly elevated low-density lipoprotein cholesterol, and reduced high-density lipoprotein cholesterol (HDL-C) levels. In type 1 diabetes, hypertriglyceridemia is a common disorder, while HDL-C levels are often normal or elevated, especially in patients with poor glycemic control. Regular monitoring of the lipid profile in diabetic patients, along with effective treatment, is essential. The most important factor is determining the appropriate CV risk category and therapeutic target. Several classes of lipid-lowering agents are available, with statins forming the cornerstone of therapy. Other agents include ezetimibe, PCSK9 inhibitors or fibrates. The aim of this article is to discuss the treatment of dyslipidemia in Poland according to the current recommendations.
REFERENCES (28)
1.
Zdrojewski T, Bandosz P, Szpakowski P, Konarski R, Jakubowski Z, Manikowski A, et al. Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. Kardiol Pol 2004; 61: 1-26.
2.
Pająk A, Wiercińska E, Polakowska M, Kozakiewicz K, Kaczmarczyk-Chałas K, Tykarski A, et al. Rozpowszechnienie dyslipidemii u mężczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. Kardiol Pol 2005; 63: 620-626.
3.
Studziński K, Tomasik T, Windak A, Banach M, Wójtowicz E, Mastej M, et al. On Behalf of the lipidogram investigators. The differences in the prevalence of cardiovascular disease, its risk factors, and achievement of therapeutic goals among urban and rural primary care patients in Poland: results from the LIPIDOGRAM 2015 study. J Clin Med 2021; 10: 5656.
4.
Jankowski P, Czarnecka D, Łukaszewska A, Łysek R, Wolfshaut-Wolak R, Bogacki P, et al. Factors related to the effectiveness of hypercholesterolemia treatment following hospitalization for coronary artery disease. Pol Arch Med Wewn 2016; 126: 388-394.
5.
Vrablik M, Seifert B, Parkhomenko A, Banach M, Jóźwiak JJ, Kiss RG, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021; 334: 66-75.
6.
Al Quran TM, Bataineh ZA, Al-Mistarehi AH, Zein Alaabdin AM, Allan H, Al Qura’an A, et al. Prevalence and pattern of dyslipidemia and its associated factors among patients with type 2 diabetes mellitus in Jordan: a cross-sectional study. Int J Gen Med 2022; 15: 7669-7683.
7.
Feingold KR. Dyslipidemia in patients with diabetes. In: Feingold KR, et al. (eds.). South Dartmouth (MA): MDText.com, Inc. 2000.
8.
Chait A, Goldberg I. Treatment of dyslipidemia in diabetes: recent advances and remaining questions. Curr Diab Rep 2017; 17: 112.
9.
Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes Ther 2016; 7: 203-219.
10.
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043-4140. Erratum in: Eur Heart J 2024; 45: 518.
11.
Solnica B, Sygitowicz G, Sitkiewicz D, Jóźwiak J, Kasperczyk S, Broncel M, et al. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci 2024; 20: 357-374.
12.
Araszkiewicz A, Borys S, Broncel M, Budzyński A, Cyganek K, Cypryk K, et al. Standards of care in diabetes. The position of Diabetes Poland – 2025. Curr Top Diabet 2025; 5: 1-158.
13.
Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, et al. Wytyczne PTL/ KLRWP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021. Nadciśn Tętn Prakt 2021; 7: 113-222.
14.
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-160.
15.
Banach M, Jankowski P, Jóźwiak J, Cybulska B, Windak A, Guzik T, et al. PoLA/CFPiP/ PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Arch Med Sci 2017; 13: 1-45.
16.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188.
17.
Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne) 2023; 14: 1239335.
18.
Banach M, Surma S, Kapłon-Cieślicka A, Mitkowski P, Dzida G, Tomasik T, et al. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association. Arch Med Sci 2023; 20: 28-42.
19.
Śliż D, Filipiak KJ, Naruszewicz M, Siebert J, Mamcarz A. Differences in achieving treatment goals with statin use in various regions of Poland – 3ST-POL study results. Ann Agric Environ Med 2016; 23: 116-119.
20.
Banach M, Rizzo M, Toth P, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11: 1-23.
21.
Bytyci I, Bajraktari G, Sahabkar A, Penson PE, Rysz R, Banach M. The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients. Eur Heart J 2021; 42: ehab724.2943.
22.
Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol 2017; 70: 1290-1301.
23.
Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-741.
25.
Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther 2015; 20: 157-168.
26.
Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, et al. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc 2019; 8: e011581.
27.
Kosmas CE, Muñoz Estrella A, Skavdis A, Genao EP, Martinez I, Guzman E. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential. Ther Clin Risk Manag 2020; 16: 1031-1037.
28.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. REDUCE-IT investigators. cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380: 11-22.
| ISSN: | 2956-5812 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
